What does Arcus Biosciences, Inc. do?

Jun 22 2025 06:55 PM IST
share
Share Via
Arcus Biosciences, Inc. is a clinical-stage biotechnology company focused on cancer immunotherapy, with a market cap of $921.20 million and recent net sales of $28 million, but a net loss of $112 million. The company does not currently pay dividends and has negative key financial metrics.
Overview:
Arcus Biosciences, Inc. is a clinical-stage biotechnology company focused on developing cancer immunotherapy within the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company. Financial Snapshot: Most recent Net Sales: 28 Million (Quarterly Results - Mar 2025) Most recent Net Profit: -112 Million (Quarterly Results - Mar 2025) Market cap: USD 921.20 Million (Micro Cap) Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.76 Return on Equity: -73.63% Price to Book: 1.73 Contact Details: Address: 3928 Point Eden Way, HAYWARD CA: 94545-3719 Tel: 1 510 6946200 Website: https://www.arcusbio.com/
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News